Corporate News – Adlai Nortye Ltd. (Ticker: ANL)
Adlai Nortye Ltd. (ANL) experienced a 5.83 % increase in share price during a 24‑hour period that ended at 04:56 PM Central Europe on Friday, 23 October 2026. The current trading price on major exchanges is USD 10.49 per share. The company’s outstanding share supply stands at 64.4 million, yielding a market capitalization of USD 725.1 million.
In the last 24 hours, approximately USD 6 million of ANL shares were traded. Compared with the previous month‑end, the share price has fallen by 32.17 %. The 200‑day simple moving average is USD 11.08. The highest price reached in the past 52 weeks was USD 17.25 on 21 April 2026, while the lowest was USD 0.88 on 9 December 2025.
Recent Corporate Event – Aeroflex Neu Limited
On 22 October 2026, Aeroflex Neu Limited (formerly Sah Polymers Limited) convened an extraordinary general meeting at its registered office in Udaipur. The meeting was chaired by Mr. Hakim Sadiq Ali Tidiwala. Two special resolutions were presented:
- Amendments to the company’s memorandum of association.
- Utilisation of proceeds from a preferential warrant issue.
Two ordinary resolutions concerned material related‑party transactions with Aeroflex Enterprises Limited and Aeroflex Finance Private Limited. Voting was conducted through a remote electronic system and by ballot paper, with a scrutineer overseeing fairness. All resolutions received the required majority and were subsequently reported to the stock exchanges and posted on the company’s website. The meeting concluded at 11:28 a.m. with no further business pending.
24‑Hour Performance of Related Shares
| Symbol | 24‑HR Change | Current Price | Market Cap (TWD) | Additional Note |
|---|---|---|---|---|
| Intelligo (7749.TW) | –1.22 % | TWD 324.5 | 15.3 bn | PE = 27.59 |
| Apex (4927.TW) | –5.15 % | TWD 53.4 | 14.9 bn | – |
| Hanchorbio (7827.TW) | –0.66 % | TWD 149.5 | 21.1 bn | Announced partnership with Aston Sci Inc. to test combined macrophage‑directed immunotherapy HCB101 and HER2‑targeted DNA vaccine AST‑301. Both assets hold U.S. FDA orphan drug designations for gastric cancer. |
| Gourmet Master (2723.TW) | +0.24 % | TWD 84.8 | 15.2 bn | – |
| Ith (6962.TW) | –2.72 % | TWD 30.35 | 15.4 bn | – |
Company Overview – Adlai Nortye Ltd.
Adlai Nortye Ltd. is a global, clinical‑stage biotechnology firm that focuses on the discovery and development of innovative cancer therapies. The company targets multiple tumour types and aims to bring novel treatments to patients worldwide.
